Video

Dr. Douglas Paauw gives updates on antihypertensives, statins, SGLT2 inhibitors


 

REPORTING FROM INTERNAL MEDICINE 2019

Douglas S. Paauw, MD, discussed why it’s been a bad year for antihypertensives, and provided updates on the side effects of statins and sodium-glucose cotransporter 2 inhibitors, in a video interview at the annual meeting of the American College of Physicians.

Dr. Paauw, professor of medicine at the University of Washington, Seattle, began by discussing some of the issues that occurred with antihypertensive drugs in the past year. These included the link between hydrochlorothiazide use and the increased risk of nonmelanoma skin cancers, the recalls of many drug lots of angiotensin II receptor blockers, and a study that found an increased risk of lung cancer in people who were taking ACE inhibitors.

He then described the findings of studies that examined the links between statins and muscle pain and other new research on these drugs.

He also warned physicians to be particularity cautious about prescribing sodium-glucose cotransporter 2 inhibitors to certain kinds of patients.

Dr. Paauw concluded by explaining why clarithromycin is his most hated drug.

Dr. Paauw is also the Rathmann Family Foundation Endowed Chair for Patient-Centered Clinical Education and the medicine clerkship director at the University of Washington.

Recommended Reading

Conservatism spreads in prostate cancer
MDedge Hematology and Oncology
Mediterranean diet cut Parkinson’s risk
MDedge Hematology and Oncology
AHA: Consider obesity as CVD risk factor in children
MDedge Hematology and Oncology
FDA: Safety signal emerged with higher dose of tofacitinib in RA study
MDedge Hematology and Oncology
Myeloma therapies raise cardiovascular risks
MDedge Hematology and Oncology
MI, strokes spike during 30 days after cancer diagnosis
MDedge Hematology and Oncology
Andexanet alfa effectively reverses factor Xa inhibition
MDedge Hematology and Oncology
AUGUSTUS: Dual surpasses triple therapy when AFib patients have PCI or ACS
MDedge Hematology and Oncology
Ticagrelor reversal agent looks promising
MDedge Hematology and Oncology
Genetic variant increases stroke risk in childhood cancer survivors
MDedge Hematology and Oncology